Skip to main content
Premium Trial:

Request an Annual Quote

QuantumBio Receives SBIR Grant for In Silico Screening Against Bioterrorism

NEW YORK, July 7 (GenomeWeb News) - QuantumBio has been awarded a Phase I Small Business Innovation Research grant for $63,353 from the US Army Research Office to apply its in silico drug-discovery tools to the study of "next-generation tools to counter bioterrorism," the company said today.

 

QuantumBio said that the project, entitled "In Silico Screening for Biothreat Countermeasures," will be conducted in collaboration with a number of undisclosed industry partners.

 

The partners will work together to further validate the use of QMScore, QuantumBio's proprietary scoring algorithm, for developing counter-bioterrorism tools, QuantumBio said.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.